Summary
The pharmacokinetics of a new sustained-release preparation of theophylline (Dilatrane à Action Prolongée capsules filled with homogenous microgranules) has been after its studied administration to 7 healthy volunteers at 8 p.m. in order to achieve therapeutic levels at night and in the morning. In separate trials the test dose of 500 or 600 mg was administered for 7 days, once daily at 8 p.m. Plasma theophylline levels were measured by capillary gas chromatography with a mass specific detector after pentylation, using internal standards labelled with stable isotopes (15N-1,3 and 13C-2 theophylline). The new sustained-release preparation showed a monophasic regular absorption phase with very low interindividual variability. After administration, the plasma level stayed within 80% of the peak levels for 8.5±1.5 h. There was a good correlation between the dose and the steady state plasma level (r=0.9587; p<0.05). This preparation can be chronically administered once daily day at 8 p.m. in order to achieve a therapeutic level during the night and the morning, and to provide sufficient protection during the nycterohemeral period, with a once dose a day schedule.
Similar content being viewed by others
References
Brazier JL, Delaye D, Désage M, Bannier A (1981) Simultaneous microdetermination of theophylline, caffeine and phenobarbital in blood collected on paper. J Chromatogr 224: 439–448
Hendeles L, Weinburger M, Johnson G (1978) Monitoring serum theophylline levels. Clin Pharmacokinet 3: 294–312
Jenne WJ, Wyze E, Rood FS, MacDonald FM (1972) Pharmacokinetics of theophylline. Application to adjustments of the clinical dose of aminophylline. Clin Pharmacol Ther 13: 349–360
Jonkman JHG, Berg WC, De Vries K, De Zeeuw RA, Schoemmaker R, Grimberg N (1981) Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained released tablet. Eur J Clin Pharmacol 21: 39–44
Jusko WJ, Gardner MJ, Mangione A, Shentag JJ, Koup JR, Vance JW (1979) Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol. J Pharm Sci 68: 1358–1366
Ogilvie RI (1978) clinical pharmacokinetics of theophylline. Clin Pharmacokinet 3: 268–293
Piafsky KM, Ogilvie RI (1975) Dosage of theophylline in bronchial asthma. N Engl J Med 292: 1218–1222
Zaska DE, Miller KW, Strem EL (1977) Oral aminophylline therapy; increased dosage requirements in children. Am Med Assoc 237: 1453–1456
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soubeyrand, J., Comet, F., Gillet, A. et al. A “once a day administration” sustained-release theophylline formulation: Disposition and pharmacokinetics. Eur J Clin Pharmacol 27, 325–328 (1984). https://doi.org/10.1007/BF00542169
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542169